Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Thomas J. Smith who wrote (3084)	2/8/1999 8:27:00 PM
From: CUBBY	Read Replies (2) \| Respond to of 4650

February 8, 1999 07:57 PM ALBUQUERQUE, N.M.--(BW HealthWire)--Feb. 8, 1999--BioModa, Inc. announced today it is now prepared to begin "Opinion Leader" testing of its TCPP Diagnostic for abnormal lung cells. BioModa's tests will be conducted in cooperation with foreign partners in Korea, China, India, Australia and Romania. "Commercial use of clinical tests in these countries represents a significant milestone reached by our research staff," stated BioModa's President, Ari Ma'ayan. "We have successfully developed strong partner relationships in Korea, China, India, Australia and Romania. These potential markets include more than two billion people and over $500 million in estimated revenues for lung cancer testing over the next 3 years." "From a humanitarian standpoint, lung cancer has reached epidemic proportions in these countries and, consequently, we are able to obtain unprecedented access through government officials. In China alone, more than one million people die of lung cancer annually, and that number continues to rise dramatically." The BioModa TCPP diagnostic can detect pre-cancerous changes in the cells lining a person's lungs several years prior to the onset of invasive carcinoma. "Obviously, earlier detection is the focus of our technology," said Jeff Garwin, MD, PhD, BioModa's chief technical officer. "We believe our test will provide the means for saving millions of lives worldwide." The test materials are currently available in the U.S. in a "bulk" format and will soon be available in a "kit" format. Upon completion of the test kit and commercial distribution of same, the company plans to follow up the TCPP lung test with additional diagnostics related to cancer in other organs of the body. In addition to their patented lung cancer test, BioModa is working on diagnostic imaging and radiopharmaceutical therapeutics for lung cancer and other cancers. About the Company BioModa, Inc. is an emerging biomedical company specializing in breakthrough cancer diagnostics and therapy. BioModa, Inc. owns a patented lung cancer test capable of detecting lung cancer up to six years earlier than any other available test and recently received efficacy confirmation from double-blind studies conducted by LungCheck(R), Inc. of Scottsdale, Ariz. BioModa's technology also encompasses the treatment of lung cancer. BioModa's prominent research team has included world-leading cytopathologists, Dr. Geno Saccomanno of St. Mary's Hospital and Medical Center, Dr. Jim Mulshine of the National Cancer Institute and the late Dr. John Frost of Johns Hopkins University. Also currently involved in BioModa's research is Dr. L. Edward Ellinwood, a nationally recognized pharmacologist from St. Mary's Hospital and Los Alamos National Laboratories. BioModa, Inc. has conducted the bulk of its research through grants, private and public investments and through an equity investment from Advanced Optics Electronics, Inc. ADOT . BioModa is currently negotiating major financing with several of the largest brokerage firms in the country. This press release contains forward-looking statements with respect to the results of operations, expectations and business of the company that involves risk and uncertainties. The company's actual future results could materially differ from those discussed. CUBBY